Shuttle Pharmaceuticals Inc (SHPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has a cash flow conversion efficiency ratio of -0.432x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-973.01K) by net assets ($2.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shuttle Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SHPH total debt and obligations for a breakdown of total debt and financial obligations.
Shuttle Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marston’s PLC
LSE:MARS
|
0.097x |
|
Trugolf Inc
NASDAQ:TRUG
|
-0.100x |
|
Aeon Metals Ltd
AU:AML
|
-0.016x |
|
WOODPECKER.CO ZY -10
F:8FG
|
N/A |
|
Property Franchise Group PLC
LSE:TPFG
|
0.089x |
|
KD Corporation
KQ:044180
|
-0.058x |
|
iSpecimen Inc
NASDAQ:ISPC
|
-0.297x |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
0.039x |
Annual Cash Flow Conversion Efficiency for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Shuttle Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see SHPH company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.25 Million | $-9.48 Million | -4.206x | +59.30% |
| 2024-12-31 | $709.15K | $-7.33 Million | -10.332x | -650.85% |
| 2023-12-31 | $4.06 Million | $-5.58 Million | -1.376x | -289.81% |
| 2022-12-31 | $7.68 Million | $-2.71 Million | -0.353x | -291.37% |
| 2021-12-31 | $-1.63 Million | $-300.34K | 0.184x | +1062.10% |
| 2020-12-31 | $-1.69 Million | $-26.83K | 0.016x | +100.08% |
| 2018-12-31 | $27.46K | $-566.69K | -20.640x | -2995.31% |
| 2017-12-31 | $-284.35K | $-202.71K | 0.713x | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more